EGFR and ovarian carcinoma: In our in vitro and in vivo studies, we demonstrated that EGFR and PAFR were overexpressed in ovarian cancer cell lines, which led us to speculate that simultaneously targeting PAFR and EGFR may be a more effective therapeutic strategy than targeting either signaling pathway alone.